Seres Therapeutics, Inc.
No SEC Form 4 filings for $MCRB in the last 30 days.
See all $MCRB insider activity →Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d124829dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS Recently announced 80% of SER-155 recipients achieved immunosuppres
Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 4 d133274dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 Execution Copy STOCK ISSUANCE AGREEMENT This STOCK ISSUANCE AGREEMENT (this “ Agreement ”) is made and entered into as of July 31, 2026 by and between Seres Therapeutics, Inc., a Delaware corporation (the “ Company ”), and
Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d100733dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 S ERES T HERAPEUTICS , I NC . 2025 I NCENTIVE A WARD P LAN ( AS AMENDED AND RESTATED EFFECTIVE July 8, 2026) I. P URPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who mak
Over the past 7 days, alphai's AI scored 2 news stories mentioning MCRB (Seres Therapeutics, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent MCRB coverage spans financial news, corporate actions and earnings.
Near-term sentiment should hinge on SER-155 irEC efficacy durability and the cash-cost reduction from lease exits, with financials boosted by the Nestlé milestone.
The filing discloses a dilutive share issuance mechanism tied to the Nasdaq closing price, creating near-term overhang risk and potential volatility around issuance timing.
The filing is a corporate governance and equity-compensation update, likely affecting dilution expectations and near-term sentiment more than fundamentals.
The webcast and trial readout can shift expectations for SER-155’s efficacy and safety in irEC, affecting near-term sentiment and risk appetite for MCRB.
The news about Seres Therapeutics (SER) does not significantly impact Microcap Research Corp (MCRB). MCRB's relevance is minimal due to lack of direct connection.
alphai scores every news story that mentions MCRB with an AI model for sentiment and relevance, and aggregates insider trades from Seres Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Seres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d124829dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING FURTHER ACTION TO REDUCE ONGOING FACILITIES COSTS Recently announced 80% of SER-155 recipients achieved immunosuppres
6 min readSeres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 4 d133274dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 Execution Copy STOCK ISSUANCE AGREEMENT This STOCK ISSUANCE AGREEMENT (this “ Agreement ”) is made and entered into as of July 31, 2026 by and between Seres Therapeutics, Inc., a Delaware corporation (the “ Company ”), and
4 min readSeres Therapeutics, Inc. (MCRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d100733dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 S ERES T HERAPEUTICS , I NC . 2025 I NCENTIVE A WARD P LAN ( AS AMENDED AND RESTATED EFFECTIVE July 8, 2026) I. P URPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who mak
2 min readSeres Therapeutics (Nasdaq: MCRB) said it will host a webcast on July 8, 2026 (8:30 a.m. ET) to discuss top-line results from an investigator-sponsored trial at Memorial Sloan Kettering of SER-155 in immune checkpoint inhibitor-related enterocolitis. The open-label study enrolled 15 patients with Grade 2–3 irEC; the primary endpoint is an immunosuppressive-free clinical response on Day 15.
3 min readSeres Therapeutics, having sold VOWST to Nestlé and reduced its workforce, has extended its financial runway until Q2 2026. The company's next significant value driver is its SER-155 program, which demonstrated strong Phase 1b data with a 77% reduction in BSI risk and received FDA Breakthrough designation for gut-driven bloodstream infections in allo-HSCT patients. Despite a relatively reasonable valuation, the risk of dilution for this thinly traded microcap warrants a "Hold" rating.
3 min readImage source: The Motley Fool.Wednesday, Nov. 5, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readCAMBRIDGE, Mass., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Seres Therapeutics, Inc. ( NASDAQ:MCRB ) , a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m.
3 min readLiquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant ( AMR ) infections Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for ...
2 min readFollowing recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies
3 min readSeres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 min read
